Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Apoptosis
    (2)
  • Arrestin
    (1)
  • Autophagy
    (1)
  • CCR
    (1)
  • CXCR
    (33)
  • Drug Metabolite
    (1)
  • Endogenous Metabolite
    (1)
  • HIV Protease
    (4)
  • Virus Protease
    (2)
  • Others
    (30)
Filter
Search Result
Results for "

CXCR

" in TargetMol Product Catalog
  • Inhibitor Products
    63
    TargetMol | Activity
  • Recombinant Protein
    5
    TargetMol | inventory
  • Peptides Products
    3
    TargetMol | natural
  • Natural Products
    3
    TargetMol | composition
  • Compound Libraries
    1
    TargetMol | Activity
CXCR2-IN-1
T109051873376-49-8In house
CXCR2-IN-1 has a pIC50 of 9.3 and is a CXCR2 antagonist of the central nervous system penetration agent.
  • $73
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CXCL-CXCR1/2-IN-1
T843252415653-55-1
CXCL-CXCR1/2-IN-1 is an orally active and potent inhibitor of the ELR+CXCL-CXCR1/2 pathway with anticancer and anti-angiogenic activity and can be used to study cardiovascular disease and cancer.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CXCR3 Antagonist 6c
T36982870998-13-3
CXCR3 antagonist 6c is an antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3).1It inhibits calcium mobilization induced by chemokine (C-X-C motif) ligand 11 (CXCL11) in HEK293 cells expressing the human receptor (IC50= 0.06 μM). It is selective for CXCR3 over a panel of 14 human G protein-coupled receptors at 10 μM. CXCR3 antagonist 6c inhibits CXCR3-mediated migration of isolated human T cells (IC50= ~100 nM). 1.Cole, A.G., Stroke, I.L., Brescia, M.-R., et al.Identification and initial evaluation of 4-N-aryl-[1,4]diazepane ureas as potent CXCR3 antagonistsBioorg. Med. Chem. Lett.16(1)200-203(2006)
  • $123
35 days
Size
QTY
CXCR7 antagonist-1
T390781613021-99-0
CXCR7 antagonist-1 is a specific antagonist of the binding of the SDF-1 chemokine or I-TAC to the chemokine receptor CXCR7. CXCR7 antagonist-1 prevents tumor cell proliferation and tumor formation and can be used in studies about inflammatory diseases.
  • $188
In Stock
Size
QTY
(R,R)-CXCR2-IN-2
T364431838123-22-0
(R,R)-CXCR2-IN-2, a diastereoisomer of CXCR2-IN-2 (compound 68), functions as a brain-penetrant CXCR2 antagonist. It exhibits a pIC50 of 9 in the Tango assay and 6.8 in the HWB Gro-α induced CD11b expression assay[1].
  • $1,900
8-10 weeks
Size
QTY
CXCR4 antagonist 1
T40786675135-69-0
CXCR4 antagonist 1 is a potent inhibitor of the CXCR4 receptor, with notable anti-HIV activity.
  • $970
Backorder
Size
QTY
CXCR2-IN-2
T369231838123-21-9
CXCR2-IN-2 is a selective CXCR2 antagonist that is brain penetrant and orally bioavailable, with IC50 values of 5.2 nM and 1 nM in the β-arrestin assay and CXCR2 Tango assay, respectively. It exhibits approximately 730-fold selectivity over CXCR1 and greater than 1900-fold selectivity over all other chemokine receptors. Furthermore, CXCR2-IN-2 effectively inhibits Gro-α induced CD11b expression in human whole blood, displaying an IC50 of 0.04 μM[1].
  • $1,400
8-10 weeks
Size
QTY
CXCR4 antagonist 2
T397422243636-57-7
CXCR4 antagonist 2 is a CXCR4 antagonist with an IC 50 value of 47 nM.
  • $970
Backorder
Size
QTY
CXCR2 antagonist 4
T61447
CXCR2 antagonist 4 (compound 7) is a highly potent antagonist that inhibits CXCR2 with an IC50 value of 0.13 μM. It also effectively inhibits the cytosolic calcium increase induced by CXCL8, with an IC50 value of 27 μM. CXCR2 antagonist 4 shows promising potential for anticancer research [1].
  • $1,520
10-14 weeks
Size
QTY
CXCR4 antagonist 7
T608111185451-72-2
CXCR4 antagonist 7 (Compound PARA-B) is able to be used in the HIV infection, inflammatory diseases, cancer, and WHIM syndrome research which is a antagonist of CXCR4 (IC 50 = 9.3 nM) [1].
  • $2,140
8-10 weeks
Size
QTY
CXCR4 antagonist 9
T616502304750-83-0
CXCR4 antagonist 9 (Compound 2) is a potent CXCR4 antagonist displaying an IC50 of 15 nM. It effectively inhibits the cytosolic calcium increase induced by CXCL12, with an IC50 value of 1.3 nM [1].
  • $2,140
6-8 weeks
Size
QTY
CXCR2 antagonist 2
T613862647464-91-1
CXCR2 antagonist 2 is a potent CXCR2 antagonist for cancer immunotherapy with an IC 50 value of 95 nM.
  • $1,900
8-10 weeks
Size
QTY
CXCR2 antagonist 5
T61235
CXCR2 antagonist 5 (compound 25) is a potent CXCR2 antagonist. CXCR2 antagonist 5 shows potent CXCR2 binding affinity ( IC 50 =0.013 μM) and calcium mobilization ( IC 50 =0.1 μM) [ 1].
  • $1,520
10-14 weeks
Size
QTY
CXCR2 antagonist 7
T61236
CXCR2 antagonist 7 (compound 19) is a potent CXCR2 antagonist. CXCR2 antagonist 7 shows potent CXCR2 binding affinity ( IC 50 =0.044 μM) and calcium mobilization ( IC 50 =0.66 μM) [ 1].
  • $1,520
10-14 weeks
Size
QTY
CXCR4 antagonist 3
T61409
CXCR4 antagonist 3 (compound 12a), an effective antagonist of CXCR4, exhibits an IC50 of 11 nM. It is a congener of TIQ15, showcasing exceptional properties such as CXCR4 antagonism, CYP 2D6 inhibition, metabolic stability, and permeability. With its potential for research on the human immunodeficiency virus, CXCR4 antagonist 3 holds great promise [1].
  • $1,520
10-14 weeks
Size
QTY
CXCR4 antagonist 8
T613632304750-84-1
CXCR4 antagonist 8 (Compound 3) is a potent inhibitor of CXCR4. It demonstrates an IC50 value of 57 nM in CXCR4 antagonism. In addition, it effectively inhibits the increase in cytosolic calcium induced by CXCL12 with an IC50 value of 0.24 nM. Furthermore, Compound 3 shows efficacy in the inhibition of CXCL12/CXCR4-mediated cell migration [1].
  • $1,520
6-8 weeks
Size
QTY
CXCR4 antagonist 4
T63369
CXCR4 antagonist 4 is an orally active and potent CXCR4 antagonist with an IC50 of 24 nM. CXCR4 antagonist 4 inhibits CYP 2D6 activity, increases PAMPA permeability, and effectively blocks entry of human immunodeficiency virus (IC50=7 nM).
  • $1,520
10-14 weeks
Size
QTY
CXCR4-IN-2
T78879
CXCR4-IN-2 (compound A1), a potent bifunctional fluorinated small molecule, inhibits CXCR4 and exhibits anticancer properties by exerting cytotoxicity (IC 50: 60 μg/mL; 72 h) and antiproliferative effects on mouse colorectal cancer (CRC) cells. It induces G2/M phase cell cycle arrest and apoptosis [1].
  • Inquiry Price
Size
QTY
CXCR4 probe 1
T643062077985-50-1
CXCR4 probe 1 (compound 5) is a potent and specific CXCR4-targeted PET tracer that acts on the CXCR4-specific antagonist TN14003 (IC50: 6.9 nM). The CXCR4 probe 1 has potential as a CXCR4-specific imaging probe for the diagnosis and prognostic monitoring of inflammatory diseases, CXCR4-positive tumours and metastatic tumours.
  • $1,520
10-14 weeks
Size
QTY
CXCR7 antagonist-1 hydrochloride
T62325
CXCR7 antagonist-1 hydrochloride is a CXCR7 antagonist that inhibits the binding of SDF-1 chemokine (also known as CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. hydrochloride can be used for the prevention of tumour cell proliferation, tumour formation, inflammatory diseases and many other diseases.
  • $1,570
10-14 weeks
Size
QTY
CXCR4 modulator-2
T623522488943-55-9
CXCR4 modulator-2 (compound Z7R) is a potent modulator of CXCR4 (IC50: 1.25 nM). CXCR4 modulator-2 exhibits good stability in mouse serum (t1/2= 77.1 min) and has anti-inflammatory effects in a mouse oedema model.
  • $2,140
6-8 weeks
Size
QTY
CXCR2 antagonist 8
T60696182498-30-2
CXCR2 antagonist 8 is a potent and selective antagonist of CXCR2 that can be used for the researching of insulin resistance [1].
  • $31
5 days
Size
QTY
CXCR2 antagonist 3
T613562647464-92-2
CXCR2 antagonist 3 (compound 11h) is a highly effective antagonist of CXC chemokine receptor 2 (CXCR2). It displays potent activity in inhibiting neutrophil infiltration into the air pouch, with double-digit nanomolar potencies against CXCR2. Moreover, CXCR2 antagonist 3 reduces the infiltration of neutrophils and MDSCs, while enhancing the infiltration of CD3+ T lymphocytes into Pan02 tumor tissues [1].
  • $2,140
8-10 weeks
Size
QTY
CXCR4 antagonist 6
T614202304750-68-1
CXCR4 antagonist 6 (compound 46) is a highly potent inhibitor of CXCR4 with an IC50 value of 79 nM. It effectively inhibits the cytosolic calcium flux induced by CXCL12, achieving an IC50 of 0.25 nM. Moreover, CXCR4 antagonist 6 demonstrates significant mitigation of cell migration mediated by the CXCL12/CXCR4 interaction. Notably, this compound exhibits remarkable efficacy in a mouse model of cancer metastasis [1].
  • $2,140
8-10 weeks
Size
QTY
CXCR4 modulator-1
T620071381178-26-2
CXCR4 modulator-1 (compound ZINC72372983) is a potent CXCR4 modulator (EC 50= 100 nM). CXCR4 modulator-1 has research value in anti-inflammatory, anticancer and anti-HIV.
  • $1,520
10-14 weeks
Size
QTY
CXCR4-IN-1
T790592304750-48-7
CXCR4-IN-1 (Example C5), with an IC50 of 20 nM, is a potent inhibitor of CXCR4, applicable for the research of various conditions such as cancer, HIV, diabetic retinopathy, and inflammation [1].
  • $1,520
6-8 weeks
Size
QTY
DOTA-CXCR4-L
T80216
DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [1].
  • Inquiry Price
Size
QTY
CXCR4 antagonist 5
T614192304749-86-6
CXCR4 antagonist 5 (compound 23), a potent CXCR4 antagonist, exhibits high inhibition efficacy against CXCR4 with an IC50 value of 8.8 nM. It effectively suppresses CXCL12-induced cytosolic calcium increase (IC50 = 0.02 nM) and hinders CXCR4/CXCL12-mediated chemotaxis. Moreover, Compound 23 demonstrates favorable physicochemical properties and in vitro safety profiles, exhibiting only marginal to moderate inhibition of CYP isozymes and hERG [1].
  • $1,520
6-8 weeks
Size
QTY
CXCR2 antagonist 6
T61359
CXCR2 antagonist 6 (compound 35c) is a potent CXCR2 antagonist. CXCR2 antagonist 6 shows potent CXCR2 binding affinity ( IC 50 =0.044 μM) and calcium mobilization ( IC 50 =0.66 μM) [ 1].
  • $1,520
10-14 weeks
Size
QTY
SX-682
T84971648843-04-2
SX-682 is a potent, selective and orally bioavailable inhibitor of CXCR1/2 ,has the potential to treat castration-resistant prostate cancer.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Elubrixin
T11179688763-64-6In house
Elubrixin (SB-656933) inhibits neutrophil CD11b upregulation (IC50 of 260.7 nM) and shape change (IC50 of 310.5 nM). Elubrixin can be used for inflammatory diseases such as inflammatory bowel disease and airway inflammation. Elubrixin is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.
  • $195
In Stock
Size
QTY
SB225002
T1955182498-32-4
SB225002 is a potent and selective CXCR2 antagonist inhibiting interleukin IL-8 binding to CXCR2.
  • $43
In Stock
Size
QTY
TargetMol | Citations Cited
Navarixin
T7130473727-83-2
Navarixin (MK-7123)(SCH527123) is a novel, selective CXC chemokine receptor 2(CXCR2) antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Reparixin
T4163266359-83-5
Reparixin (Repertaxin) is a potent inhibitor of both CXCL8 receptors CXCR1/2, it inhibits weakly CXCR2-mediated cell migration (IC50=100 nM), whereas it strongly blocks CXCR1-mediated chemotaxis (IC50=1 nM).
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
AMG 487
T10297L473719-41-4
AMG 487 is a potent and selective antagonist of chemokine (C-X-C motif) receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
Plerixafor
T1776110078-46-1
Plerixafor (AMD-3329), a chemokine receptor antagonist, blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4.
  • $42
In Stock
Size
QTY
TargetMol | Citations Cited
Plerixafor octahydrochloride
T1776L155148-31-5
Plerixafor octahydrochloride (JM3100 octahydrochloride) blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation. Plerixafor is a bicyclam with hematopoietic stem cell-mobilizing activity.
  • $42
In Stock
Size
QTY
TargetMol | Citations Cited
MSX-130
T40334051-59-6
MSX-130 is CXCR4 Antagonist.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
AMD 3465 hexahydrobromide
T7208185991-07-5
AMD 3465 hexahydrobromide (GENZ-644494 (hexahydrobromide)) is a CXCR4 receptor antagonist with potential anticancer and anti-HIV activity.
  • $34
In Stock
Size
QTY
TargetMol | Inhibitor Sale
WZ811
T173955778-02-4
WZ811 is a novel and effective small molecular CXCR4 antagonist (EC50: 0.3 nM).
  • $48
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Danirixin
T5193954126-98-8
Danirixin (GSK1325756) is a potent antagonist of CXCR2 that inhibits IL-8 binding to CXCR2 (IC50: 12.5 nM).
  • $56
In Stock
Size
QTY
TargetMol | Inhibitor Sale
CXCR7 modulator 2
T109072227426-37-9
CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM.
  • $643
10-14 weeks
Size
QTY
Mavorixafor
TQ0174558447-26-0
Mavorixafor (AMD-070) is an effective and selective antagonist of CXCR4, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Mavorixafor inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells (IC50 = 1 nM) and PBMCs (IC50 = 9 nM).
  • $64
In Stock
Size
QTY
VUF11207 fumarate
T133241785665-61-3
VUF11207 fumarate is an agonist of CXCR7 and a high-potency ligand of CXCR7 (pKi: 8.1).
  • $36
In Stock
Size
QTY
CXCR7 modulator 1
T109062231812-31-8
CXCR7 modulator 1 is an effective and orally bioavailable peptoid hybrid CXCR7 modulator with Ki of 9 nM.
  • $1,280
Backorder
Size
QTY
Decursin
T3S14165928-25-6
1. Decursin (Decursinol angelate) is able to attenuate kainic acid-induced seizures and could have potential as an antiepileptic drug. 2. Decursin exhibits hepatoprotective effects , potentially by inhibiting the TGF-β1 induced NOX activation and Smad signaling. 3. Decursin has anti-cancer activity , mediated suppression of the PKCα, MAPK and NF-κB pathways in MCF-7 cells. 4. Decursin exhibits cytotoxicity against various human cancer cells and to possess anti-amnesic activity in vivo through the inhibition of AChE activity.
  • $36
In Stock
Size
QTY
Ladarixin Sodium
T27791865625-56-5
Ladarixin Sodium, an Chemokine CXCR antagonist, is used potentially for the treatment of type I diabetes.
  • $177
5 days
Size
QTY
Reparixin L-lysine salt
T12705266359-93-7
Reparixin L-lysine salt (Repertaxin L-lysine salt) is an allosteric chemokine receptor 1/2 (CXCR1/2) activation inhibitor.
  • $39
In Stock
Size
QTY
AZD-5069
T7681878385-84-3
AZD-5069 is an chemokine receptor 2 antagonist (CXCR2; IC50 = 0.79 nM).
  • $46
In Stock
Size
QTY
Baohuoside I
T3396113558-15-9
Baohuoside I (Icariside-II) is a component of Epimedium koreanum, exhibits anti-inflammatory activity and anti-osteoporosis activities.
  • $30
In Stock
Size
QTY